Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Legend Biotech Corporation is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel cell therapies for the treatment of cancer and other serious diseases. The company operates primarily in the biotechnology and pharmaceutical industries, with a strong emphasis on chimeric antigen receptor T-cell (CAR-T) therapies. Its core value proposition is the development of differentiated, next-generation cell therapies that aim to improve efficacy, durability of response, and patient outcomes compared to earlier CAR-T approaches.
The company’s primary revenue driver to date has been collaboration and licensing arrangements, most notably its global partnership with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson, for the development and commercialization of its lead CAR-T product. Legend Biotech was founded in 2014 in China and subsequently expanded its global footprint, including establishing a presence in the United States. The company completed its initial public offering on the Nasdaq in 2020, marking its transition to a publicly traded, globally oriented biotechnology company.
Business Operations
Legend Biotech’s operations are centered on research and development of cell therapies, with its business organized around oncology-focused product candidates. Its lead product, ciltacabtagene autoleucel (cilta-cel), is a BCMA-targeted CAR-T therapy developed for the treatment of multiple myeloma and represents the company’s most advanced and commercially impactful asset. Revenue generation has primarily come from collaboration revenue, milestone payments, and cost-sharing arrangements rather than direct product sales.
The company conducts research, clinical development, and manufacturing through a combination of internal capabilities and strategic partnerships. It operates development and manufacturing facilities in China, the United States, and Europe, and leverages proprietary CAR-T platforms and cell-processing technologies. The collaboration with Janssen Biotech, Inc. includes shared development responsibilities and global commercialization, while Legend Biotech retains significant involvement in manufacturing and ongoing innovation.
Strategic Position & Investments
Legend Biotech’s strategic direction is focused on expanding the clinical and commercial potential of its CAR-T platform, both within multiple myeloma and across additional hematologic malignancies and solid tumors. The company continues to invest heavily in clinical trials, next-generation CAR constructs, and manufacturing process optimization to support scalability and regulatory compliance in multiple jurisdictions.
Key strategic investments include continued development of follow-on CAR-T candidates and lifecycle management initiatives for ciltacabtagene autoleucel, as well as investment in advanced cell therapy manufacturing infrastructure. While the company does not operate as a diversified holding company, its most notable strategic asset remains its collaboration with Janssen Biotech, Inc., which provides access to global commercialization capabilities, regulatory expertise, and capital resources.
Geographic Footprint
Legend Biotech operates across several major global regions, with corporate and research activities spanning Asia, North America, and Europe. The company maintains operational headquarters in China, with a U.S. presence in New Jersey, which supports clinical development, regulatory engagement, and partnership management. European operations primarily support clinical trials and regulatory activities.
Its geographic footprint reflects a strategy of integrating innovation originating in China with global development and commercialization infrastructure. Through its partnership with Janssen Biotech, Inc., Legend Biotech has achieved significant market presence in the United States, Europe, and other international markets where its lead therapy has received regulatory approvals or is under review.
Leadership & Governance
Legend Biotech is led by an experienced management team with backgrounds in biotechnology, pharmaceuticals, and global drug development. The leadership emphasizes scientific innovation, disciplined clinical execution, and strategic collaboration as core elements of the company’s governance and operating philosophy.
Key executives include:
- Frank Zhang – Chairman and Chief Executive Officer
- Ying Huang – Chief Financial Officer
- Yu Yuan – Chief Scientific Officer
- Michael Yeh – President and Head of U.S. Operations
- Jun Peng – Chief Medical Officer
The company is governed by a board of directors with experience in biotechnology, capital markets, and multinational operations, supporting Legend Biotech’s strategy of global expansion and long-term value creation through innovative cell therapies.